CRINETICS PHARMACEUTICALS, INC. Financials Crinetics Pharmaceuticals, Inc.
Equities
CRNX
US22663K1079
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.12 USD | -0.40% |
|
-1.98% | +18.38% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 607.7 | 464.5 | 1,340 | 984.7 | 2,377 | 3,317 | - | - |
| Enterprise Value (EV) 1 | 489.3 | 293.7 | 1,006 | 650.3 | 1,818 | 2,794 | 2,860 | 3,074 |
| P/E ratio | -12 x | -5.83 x | -10.1 x | -5.81 x | -9.64 x | -12.8 x | -11.7 x | -12 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 509 x | 6,543 x | 1,243 x | 208 x | 592 x | 2,213 x | 119 x | 37.9 x |
| EV / Revenue | 410 x | 4,136 x | 933 x | 137 x | 453 x | 1,864 x | 103 x | 35.1 x |
| EV / EBITDA | -9.24 x | -3.97 x | -9.42 x | -3.9 x | -8.21 x | -10.6 x | -10.6 x | -11 x |
| EV / FCF | -10.4 x | -4.72 x | -11.3 x | -5.56 x | -10.6 x | -13.3 x | -13.4 x | -12.2 x |
| FCF Yield | -9.58% | -21.2% | -8.85% | -18% | -9.4% | -7.5% | -7.48% | -8.2% |
| Price to Book | 5.18 x | 2.54 x | 3.29 x | 3.12 x | 4.5 x | 4.99 x | 5.61 x | 6.76 x |
| Nbr of stocks (in thousands) | 24,222 | 32,922 | 47,157 | 53,810 | 66,799 | 78,744 | - | - |
| Reference price 2 | 25.09 | 14.11 | 28.41 | 18.30 | 35.58 | 42.12 | 42.12 | 42.12 |
| Announcement Date | 3/9/20 | 3/30/21 | 3/30/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.193 | 0.071 | 1.078 | 4.737 | 4.013 | 1.499 | 27.9 | 87.62 |
| EBITDA 1 | -52.94 | -74 | -106.8 | -166.9 | -221.5 | -263.3 | -269.1 | -279.3 |
| EBIT 1 | -53.83 | -74.95 | -107.7 | -167.9 | -222.6 | -260.1 | -274.4 | -274.8 |
| Operating Margin | -4,512.32% | -105,567.61% | -9,990.91% | -3,544.06% | -5,547.17% | -17,351.73% | -983.57% | -313.66% |
| Earnings before Tax (EBT) 1 | -50.42 | -73.81 | -107.6 | -163.9 | -209.3 | -243.8 | -258.2 | -242.3 |
| Net income 1 | -50.42 | -73.81 | -107.6 | -163.9 | -214.5 | -245.1 | -272.1 | -275.9 |
| Net margin | -4,226.49% | -103,960.56% | -9,985.25% | -3,460.38% | -5,345.85% | -16,352.45% | -975.42% | -314.87% |
| EPS 2 | -2.090 | -2.420 | -2.800 | -3.150 | -3.690 | -3.299 | -3.610 | -3.506 |
| Free Cash Flow 1 | -46.87 | -62.21 | -89.02 | -116.9 | -171 | -209.5 | -214 | -252 |
| FCF margin | -3,929% | -87,623.94% | -8,258.26% | -2,466.98% | -4,261.03% | -13,976.82% | -767.02% | -287.6% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/20 | 3/30/21 | 3/30/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.078 | 3.131 | 0.439 | 0.458 | 0.709 | 2.679 | 0.988 | 0.346 | - | 0.1 | 0.6 | 0.1 | 0.6 | 0.0332 |
| EBITDA 1 | -27.57 | -30.65 | -33.59 | -42.83 | -43.21 | -47.28 | -47.7 | - | - | -62.4 | -60.07 | -62.68 | -65.77 | -69.39 | - |
| EBIT 1 | -27.81 | -30.89 | -33.83 | -43.04 | -43.45 | -47.56 | -47.98 | -53 | -58.98 | -62.66 | -63.35 | -65.14 | -67.29 | -68.97 | -68.13 |
| Operating Margin | - | -2,865.31% | -1,080.39% | -9,805.24% | -9,487.77% | -6,707.48% | -1,790.89% | -5,363.87% | -17,045.38% | - | -63,346.42% | -10,856.86% | -67,291.62% | -11,494.55% | -204,914.29% |
| Earnings before Tax (EBT) 1 | -27.85 | -30.79 | -34.63 | -42.38 | -41.92 | -44.99 | -46 | -50.98 | -57.46 | -55.9 | -59.58 | -61.36 | -63.62 | -65.27 | -65.01 |
| Net income 1 | -27.85 | -30.79 | -34.63 | -42.38 | -41.92 | -44.99 | -46 | -50.98 | -57.46 | -60.1 | -60.21 | -61.43 | -63.55 | -65.29 | -65.01 |
| Net margin | - | -2,856.59% | -1,105.94% | -9,652.62% | -9,153.93% | -6,345.7% | -1,716.87% | -5,159.82% | -16,606.36% | - | -60,213.42% | -10,237.52% | -63,554.08% | -10,881.73% | -195,529.83% |
| EPS 2 | -0.7300 | -0.6800 | -0.7300 | -0.8100 | -0.7800 | -0.8400 | -0.8500 | -0.9400 | -1.010 | -0.9000 | -0.8153 | -0.8020 | -0.8411 | -0.8534 | -0.9075 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/5/21 | 3/30/22 | 5/12/22 | 8/12/22 | 11/14/22 | 2/28/23 | 5/4/23 | 8/8/23 | 11/7/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 118 | 171 | 334 | 334 | 559 | 523 | 457 | 243 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -46.9 | -62.2 | -89 | -117 | -171 | -210 | -214 | -252 |
| ROE (net income / shareholders' equity) | -36.4% | -51.6% | -43% | -50.6% | -50.2% | -43.7% | -42.1% | -47.5% |
| ROA (Net income/ Total Assets) | -33.4% | -47% | -40.3% | -46.6% | -43.4% | -39.3% | -35.4% | -40.8% |
| Assets 1 | 150.9 | 156.9 | 267.2 | 351.6 | 493.8 | 623.3 | 768.2 | 676.3 |
| Book Value Per Share 2 | 4.850 | 5.550 | 8.640 | 5.870 | 7.910 | 8.430 | 7.510 | 6.230 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.49 | 0.19 | 0.44 | 1.66 | 4.69 | 1 | 7.5 | 14 |
| Capex / Sales | 41.24% | 261.97% | 40.45% | 34.96% | 116.82% | 66.72% | 26.88% | 15.98% |
| Announcement Date | 3/9/20 | 3/30/21 | 3/30/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
42.12
USD
Average target price
57.23
USD
Spread / Average Target
+35.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.38% | 3.32B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CRNX Stock
- Financials Crinetics Pharmaceuticals, Inc.
